NUWE
NUWELLIS (NUWE)
NASDAQ
$0.50-$0.10 (-16.24%)
Price as of Jun 03, 2026 7:17 PM EDT
  • $2.1M
    Market Cap
  • -98.17%
    1-Year Change
  • Medical Devices
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 39
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Nuwellis, Inc. Announces First Quarter 2026 Financial Results

Nuwellis, Inc. (NUWE) reported Q1 2026 net sales of $2.4 million, up 26% year-over-year, with gross margin improving to 70.1%. The company completed the Rendiatech acquisition, appointed new CFO and board members, and expanded commercial coverage. However, the company posted a net loss of $4.3 million and held only $2.2 million in cash with no debt.

05/12/2026, 8:00 AMGlobeNewswire

Nuwellis Completes Acquisition of Rendiatech

Nuwellis (NASDAQ: NUWE) has completed its acquisition of Rendiatech, an Israeli developer of automated kidney function monitoring technology. The acquisition expands Nuwellis' capabilities in fluid management and kidney function monitoring, complementing its existing Aquadex SmartFlow System. The technology enables continuous renal monitoring with real-time data capture to support clinical decision-making in critically ill patients.

03/17/2026, 8:00 AMBenzinga

Nuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advancing Its Cardiorenal Portfolio Strategy

Nuwellis (NASDAQ: NUWE) announced a definitive agreement to acquire Rendiatech Ltd., an Israeli medical technology company specializing in automated kidney function monitoring. The acquisition expands Nuwellis' cardiorenal portfolio beyond therapeutic fluid management into real-time renal diagnostics, leveraging Rendiatech's Clarity system for continuous urine-output measurement. The transaction is expected to close following customary conditions and will be integrated using Nuwellis' existing commercial infrastructure.

01/29/2026, 4:35 PMBenzinga

Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company

Nuwellis has signed a non-binding letter of intent to acquire Rendiatech, an Israeli medical device company specializing in real-time urine flow and acute kidney injury monitoring technologies, potentially expanding its fluid management technology platform.

08/19/2025, 8:15 AMBenzinga

Nuwellis Stockholders Approve All Proposals at Special Meeting

Nuwellis held a Special Meeting of Stockholders, where shareholders approved proposals to increase authorized shares, potentially conduct a reverse stock split, and issue shares from a recent financing to enhance financial flexibility.

08/04/2025, 5:24 PMGlobeNewswire

Why Nuwellis Shares Are Exploding Today: A 200% Surge Explained

Nuwellis Inc experienced a dramatic 200% stock surge in premarket trading after receiving a new U.S. patent for an improved extracorporeal blood filtering machine that enhances fluid balance calculation accuracy in continuous renal replacement therapy systems.

07/16/2025, 10:07 AMInvesting

Why Nuwellis Shares Are Exploding Today: A 200% Surge Explained

Nuwellis Inc experienced a dramatic 200% stock surge in premarket trading after receiving a new U.S. patent for an innovative extracorporeal blood filtering machine that improves fluid balance calculation accuracy in continuous renal replacement therapy systems.

07/16/2025, 9:31 AMInvesting

Nuwellis Soars 31.25% In After-Hours Trading — What's Behind The Surge?

Nuwellis experienced a significant stock price surge of 31.25% in after-hours trading following the announcement of securing a key patent for its fluid management technology and bringing back veteran CEO John Erb.

07/16/2025, 1:38 AMBenzinga

Peers

Statistics

More
Day Range
$0.54
$0.71
$0.59
1-Year Range
$0.20
$15.95
$0.59
Latest Close$0.59
Change
-$0.11 (-18.46%)
Volume342,356
Market Cap$2.1M
Shares Outstanding2.7M
P/E (TTM)-0.003
Diluted EPS (TTM)-$227.15
Enterprise Value-$8,903.00

Information as of 06/02/2026

Company Profile

$2.1M
Market Cap
-$19.0M
Net Income
Sector: Healthcare
Industry: Medical Devices
12988 Valley View Road, Eden Prairie, MN, United States, 55344
952 345 4200

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through specialty healthcare distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

Key Executives

  • Neil Ayotte
  • John L. Erb
  • David Lerner
  • Betsy Riemenschneider
  • Leah McMullen

Current Ownership Distribution

  • Institutions4.2M (40.20%)
  • Mutual Funds4.0M (37.95%)
  • Insiders2.3M (21.85%)
  • Other0 (0.00%)